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Abstract
The role of chemokines during some viral infections is unpredictable because the inflammatory
response regulated by these molecules can have two, contrasting effects—viral immunity and
immunopathologic injury to host tissues. Using Theiler’s virus infection of SJL mice as a model of
this type of disease, we have investigated the roles of two chemokines—regulated on activation,
normal T cell-expressed and secreted (RANTES) chemokine and monokine induced by IFN-c
(MIG)—by treating mice with antisera that block lymphocyte migration. Control, infected mice showed
virus persistence, mild inflammation and a small degree of demyelination in the white matter of the
spinal cord at 6 weeks post-infection. Treatment of mice with RANTES antiserum starting at 2 weeks
post-infection increased both viral antigen expression and the severity of inflammatory demyelination
at 6 weeks post-infection. MIG antiserum increased the spread of virus and the proportion of spinal
cord white matter with demyelination. Overall, viral antigen levels correlated strongly with the extent
of pathology. At the RNA level, high virus expression was associated with low IL-2 and high IL-10
levels, and RANTES antiserum decreased the IL-2/IL-10 ratio. Our results suggest that RANTES and
MIG participate in an immune response that attempts to restrict viral expression while limiting
immunopathology and that anti-chemokine treatment poses the risk of exacerbating both conditions
in the long term.
Introduction
Infection of susceptible SJL mice intracranially with Theiler’s
murine encephalomyelitis virus (TMEV) virus induces a bi-
phasic disease. The first phase is characterized by transient
encephalitis within the first 2 weeks of infection due to rapid
viral replication in the brain. In the second phase the virus
moves to the spinal cord at 7–14 days post-infection (d.p.i.)
and establishes lifelong infection in the white matter of the
cord. The Daniel’s strain (DA) of TMEV persists within
oligodendrocytes, astrocytes and macrophages/microglia.
Viral persistence results in chronic inflammation by lympho-
cytes and macrophages, as well as activation of central
nervous system (CNS) glia, which leads to extensive de-
myelination, axonal degeneration and progressive neurolog-
ical deficits starting at 2–3 months post-infection.
Theiler’s virus induces the production of a variety of
chemokines in the CNS—molecules that regulate migration
and function of inflammatory cells. Similar patterns of chemo-
kine expression develop in the CNS after infections with
different strains of TMEV and with other viruses (1–11). Some
of the major chemokines are regulated on activation, normal
T cell-expressed and secreted chemokine (RANTES; CCL5),
monokine induced by IFN-c (MIG; CXCL9), interferon-c
inducible protein-10 (IP-10; CXCL10), monocyte chemotactic
protein-1 (MCP-1; CCL2), macrophage inflammatory protein-
1a (MIP-1a; CCL3) and MIP-1b (CCL4). Most are up-regulated
within several days of infection and remain elevated as long as
viral infection and/or tissue injury persists. A primary role for
these chemokines is to facilitate infiltration of virus-reactive
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lymphocytes. For example, lymphocyte infiltration promoted
by MIG and IP-10 during mouse hepatitis virus (MHV) infection
serves to limit viral replication and reduce mortality (12–14). In
contrast, inflammatory responses also potentially are injurious
to normal tissues, and therefore under some conditions
chemokine production could be harmful. Theiler’s virus
infection of SJL mice is one such example where the role of
chemokines cannot be easily predicted because the in-
flammatory response has two prominent and contrasting
effects. CD4 and CD8 lymphocytes are necessary for
preventing mortality throughout infection, but their infiltration
into the CNS over the long term also leads significantly to
myelin and axonal destruction. Antiviral responses in SJL mice
are insufficient to clear virus, at least in part due to a lack of
virus reactivity of most infiltrating lymphocytes (15). Therefore,
virus and the resulting inflammatory response persist lifelong
in the spinal cord. The secondary development of autore-
activity might also play a role in chronic disease (16). Thus,
chemokines probably exert both positive and negative effects
concurrently in this model.
The two chemokines that we investigated in the present
study were RANTES and MIG. Our protocol was to treat mice
with one or two doses of neutralizing antiserum to either of
these chemokines and examine the effects on viral load,
cytokine mRNAs and spinal cord pathology 1 month later. In
designing this protocol, our primary focus was spinal cord
pathology because the degree of motor dysfunction correlates
strongly with the extent of spinal cord injury (17, 18). Since
CNS injury is a long-term manifestation of infection, a suffi-
ciently long treatment period was required to detect changes
in pathology if they developed. Moreover, by limiting the
number of antiserum treatments we attempted to reduce
immunopathology without significantly affecting virus load.
Indeed, we found that virus expression increased only slightly,
but counter to our hypothesis, spinal cord pathology also
increased rather than decreased by 1-month post-treatment.
Methods
Mice and experimental design
Six- to eight-week old SJL/J mice (Jackson Laboratories, Bar
Harbor, ME, USA) were intra-cerebrally injected with 2.03 106
plaque-forming unit (p.f.u.) of Daniel’s strain of TMEV. At the
described times mice were injected intra-peritoneally with
0.5 ml chemokine antiserum (provided by Tom Lane) or normal
goat serum (Sigma, St Louis, MO, USA). Chemokine antisera
were made by injection of rabbits (for MIG antiserum) or goats
(for RANTES antiserum) with peptide–keyhole limpet hemo-
cyanin conjugates corresponding to the specific chemokines.
The antisera reacted specifically with the cognate chemokines
and blocked CD4 and CD8 lymphocyte migration in vivo in
previous studies (7, 14, 19, 20). The antibodies also were
expected to be efficacious during Theiler’s virus infection
because Ig delivered systemically are detectable in the CNS
(21, 22). We estimate that a single injection resulted in
a neutralizing antibody concentration of 0.25 mg ml1, based
on an approximate blood volume of 2 ml per mouse. All animal
protocols were approved by the Mayo Institutional Animal Care
and Use Committee.
Three separate experiments were conducted. In each
experiment mice were treated with chemokine antiserum
(anti-RANTES or anti-MIG) or normal goat serum once or
twice (separated by 7 days) starting at 10 d.p.i. Analyses of
RNA levels, virus expression and pathology were conducted
1 month following the last antiserum treatment. Data from
multiple experiments were combined because single and
double antiserum administrations were considered to have
similar effects. Single antibody injections are sufficient to
neutralize target antigens in vivo (23), and the effective
antibody concentration in the serum was unlikely to be
significantly prolonged by a second injection (1–3 week Ig
half-life), compared with the 4-week span of each experiment.
The relatively late analysis was chosen to be able to detect
possible changes in spinal cord pathology, which typically
manifest many days or weeks following immunomodulatory
treatments. In the Theiler’s virus model we typically observe no
mortality beyond 10 d.p.i., and functional deficits do not
become obvious until ~3 months post-infection. Treatment with
either chemokine antiserum neither increased mortality nor
induced functional deficits.
Antiserum-neutralizing activity
In vitro chemotaxis assays were used to demonstrate
chemokine-neutralizing activity of anti-MIG and anti-RANTES
antiserum. For anti-MIG, 5 3 105 CXCR3+ 300-19 lymphocytic
cells (generously provided by B. Moser) were re-suspended in
RPMI + 1% FBS and placed in the top chamber of a Multiscreen-
MIC S510 transwell plate (96-well, 5lM pore size; Millipore,
Billerica, MA, USA). The bottom well contained either recombin-
ant mouse MIG (Biosource, Camarillo, CA, USA) 200 ng ml1
alone or recombinant mouse MIG (200 ng ml1) pre-incubated
with anti-MIG antisera at varying concentrations (200, 100, 50 ug
ml1). All samples were performed in duplicate. For anti-
RANTES determination, splenocytes were isolated from mice
that had been immunized with MHV (23 105 p.f.u.) 7 days prior
and expressed CCR5, a RANTES receptor (24, 25). A total of
53 105 splenocytes were re-suspended in RPMI + 1% FBS and
chemotaxis was determined as above using recombinant
mouse RANTES (Biosource) and anti-RANTES antisera in place
of MIG and anti-MIG antisera. Assay plates were incubated at
37C for 2 h and migration was determined by counting the
number of cells in the bottom well in five random high power
fields (3200) for each sample. Migration is presented as
a chemotactic index that is calculated by dividing the number
of cells that migrated in response to signal by the number of cells
responding to medium alone (26).
Pathologic analysis
Mice were over-dosed with sodium pentobarbital and per-
fused by intra-cardiac puncture with Trump’s fixative. Spinal
cords were removed and analyzed on coded sections as
follows:
(i) Spinal cord lesion frequency: Dissected spinal cords were
cut into 1-mm blocks, and every third block was
embedded in glycol methacrylate. Coronal, cross-sections
were stained with a modified erichrome stain with a cresyl
violet counterstain to demonstrate demyelination and
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inflammation, as previously described (27). Lesions were
quantified by determining the percentage of spinal cord
quadrants (four possible quadrants per section) showing
any sign of pathology from an average of 10 sections per
spinal cord.
(ii) Spinal cord lesion severity: Lesion severity was assessed
from coded, spinal cord sections (prepared above)
without knowledge of experimental group. Each spinal
cord quadrant showing pathology was scored according
to the following 4-point scale: Grade 1 = mild lymphocyte
infiltration; Grade 2 = mild lymphocyte and macrophage
infiltration and minimal demyelination; Grade 3 = moder-
ate inflammation and demyelination; Grade 4 = extensive
inflammation, demyelination and severe tissue damage.
All analyses were done without knowledge of the treatment
groups.
Immunostaining and virus antigen quantitation
Alternate blocks from the same, Trump’s-fixed spinal cords as
for pathologic analyses, were embedded in paraffin. Cross-
sections were collected for immunostaining virus antigen with
polyclonal, rabbit antiserum to purified DA virus (28) followed
by biotinylated, secondary antibodies and ABC reagent
(Vector Laboratories, Burlingame, CA, USA). Viral antigen
expression was measured as the percentage of spinal cord
quadrants with infected cells and by the total number of
infected cells relative to the total cross-sectional area exam-
ined. Cross-sectional areas were measured using a ZIDAS
interactive camera lucida system attached to a Zeiss photo-
microscope. Ten sections from each spinal cord were analyzed
for virus expression, and sections were analyzed without
knowledge of experimental group.
Immunostaining for CD4 and CD8 T cells was performed on
cryosections from freshly frozen spinal cords from additional
mice. Cells were detected using CD4 and CD8 mAbs (BD-
Pharmingen, San Diego, CA, USA), followed by biotinylated,
secondary antibodies and ABC reagent (Vector Laboratories).
Real-time reverse transcriptase–PCR
Spinal cords and brain stems were collected immediately after
over-dosing mice with sodium pentobarbital. Total RNA was
isolated using RNA STAT-60 (Tel-Test Inc., Friendswood, TX,
USA) and stored at 80C. RNA levels were determined by
real-time reverse transcriptase (RT)–PCR using a LightCycler
instrument (Roche Diagnostics, Mannheim, Germany) and
Qiagen QuantiTect RT–PCR (SYBR Green) kits (Valencia, CA,
USA). Primer sequences are shown in Table 1. Standard curves
for quantifying sample RNA were generated from plasmids
containing the complete cDNA sequences for the specific
genes. Cloning of PCR-amplified cDNAs was performed with
Promega pGEM-T Easy kits and DH5a (Library grade)
Escherichia coli. Plasmids from positive transformants were
isolated with Qiagen Miniprep spin columns. Standards were
amplified with the same reaction mixtures and conditions as the
experimental samples and had single melting peaks and linear
product-cycle regressions over a 5-log range of input plasmid.
Twenty nanograms of total sample RNA was used in each
reaction, an amount found in titration experiments to be optimal
for detecting differences in RNA levels. Reaction conditions
were as follows:reverse transcription 50C for 20 min, de-
naturation 95C for 15 min, amplification (35 cycles) 95C for
10 s + 57C for 10 s + 72C for 15 s and melt 0.1C s1. Reaction
controls included water alone or experimental samples made
through mock RNA isolation (tissue excluded). No specific
reaction product was amplified in control reactions, as in-
dicated by melting curves and electrophoresis. Experimental
samples that gave reaction products with melting peaks lower
than those expected (e.g. water reaction) were considered
below the limit of detection.
Statistics
Each experimental group was compared individually with the
appropriate control group and statistically significant differ-
ences were determined by non-parametric Student’s t test
(Mann–Whitney) with significance set at P< 0.05. Correlations
were determined using the Spearman non-parametric
coefficient.
Results
Neutralizing activity of chemokine antiserum
The roles of RANTES and MIG during early stages of Theiler’s
virus infection were investigated using neutralizing, rabbit or
goat antisera. These antisera were shown previously to reduce
lymphocyte infiltration and disease course in a tumor model
and during MHV infection (7, 19, 20). The neutralizing activities
were confirmed using in vitro chemotaxis assays. Cells
responsive to RANTES (splenocytes from MHV-infected
mice) or MIG (300-19 cell line) were seeded into the upper
chamber of transwell plates, and recombinant chemokines
and antisera were placed in the bottom chamber. Cell
migration into the bottom chamber was induced by the
presence of the chemokines. Anti-MIG antiserum reduced
cell migration by a maximum of 75%, whereas anti-RANTES
blocked migration completely (Fig. 1). Thus, these antisera
neutralized most or all chemokine-specific activity.
Table 1. RT–PCR primer sequences
Gene Forward primer Reverse primer
VP2 59-TGGTCGACTCTGTGGTTACG-39 59-GCCGGTCTTGCAAAGATAGT-39
GAPDH 59-CCATGTTTGTGATGGGTGTG-39 59-GATGCAGGGATGATGTTCTG-39
CXCR3 59-AACTCTTCCATTGTGGGCAG-39 59-AAGGCCCCTGCATAGAAGTT-39
IL-2 59-GCAGGCCACAGAATTGAAAG-39 59-TCCACCACAGTTGCTGACTC-39
IL-10 59-GCCTTGGGAAGCAATTGAAG-39 59-AACTGGCCACAGTTTTCAGG-39
IFN-c 59-GAGGAACTGGCAAAAGGATG-39 59-TGAGCTCATTGAATGCTTGG-39
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IL-2 and IL-10 gene expression correlates with chemokine
neutralization and virus expression
Anti-MIG and anti-RANTES antisera were administered in-
dividually to mice by intra-peritoneal injections starting at
10 days after infection with Theiler’s virus. Analyses were
conducted 1 month later. Since viral load and the immune
responses triggered by virus are major factors regulating CNS
pathology in this model, we looked for changes in mRNA
levels for a variety of viral and immune-related genes. Real-
time RT–PCR was performed with RNA isolated from homoge-
nates of spinal cords and brain stems. Data from two, separate
experiments were combined. In one experiment mice were
treated with antiserum at 10 and 17 d.p.i. and analyzed at 56
d.p.i. (39 days post-treatment interval), and in the other
experiment mice were treated once at 12 d.p.i. and analyzed
at 48 d.p.i. (36 days post-treatment interval). Average RNA
levels for most genes examined were not significantly affected
by antiserum treatment, including VP2 viral capsid protein,
CXCR3 chemokine receptor, IFN-c, IL-2, IL-4 or GAPDH (Fig.
2). One exception was a modest increase in IL-10 mRNA by
RANTES antiserum (Fig. 2D). When gene expression for each
of these molecules was analyzed in the two experiments
separately, only for IL-10 were mRNA levels different between
treatment and control groups following two antiserum injec-
tions but not following a single injection. Thus, chemokine
neutralization had few, lasting effects on the expression of
immune-related genes.
More interestingly, we discovered important relationships
among IL-2, IL-10 and VP2. Firstly, expression of IL-2 was
inversely related to the expression of IL-10 (r = 0.58, P <
0.0001; Fig. 2E). Mice with high IL-2 levels had low IL-10 levels
in the CNS, and vice versa. Secondly, analysis of the IL-2/IL-10
ratio revealed a shift toward IL-10 expression with anti-RANTES
treatment (P = 0.02; Fig. 2F). Thirdly, we found that levels of
both IL-2 and IL-10 correlated VP2. That is, IL-2 RNA
decreased (r = 0.50, P = 0.01; Fig. 3A) and IL-10 increased
(r = 0.88, P< 0.0001; Fig. 3B) in proportion to increasing levels
of VP2 RNA. Finally, the IL-2/IL-10 ratio correlated strongly with
levels of VP2 RNA (r=0.73,P<0.0001; Fig. 3C). Mice with the
lowest ratio of IL-2/IL-10 had the highest levels of VP2.
Interestingly, the cytokine RNA levels varied across only a
3-fold range (0.5 log units) while VP2 RNA levels varied across
a 100-fold range (2 log units). Since these correlations were
found independent of specific antiserum treatments, the results
indicate close relationships between IL-2, IL-1, and virus
expression within a larger context of virus–host interactions.
Chemokine neutralization increases viral antigen
expression
We further examined the effect of RANTES or MIG neutraliza-
tion on virus expression by immunohistochemical detection
and quantitation of virus in spinal cord cross-sections (10 per
animal). This type of analysis is the most informative measure
of virulence, as viral antigen expression in the spinal cord has
been shown to correlate with the extent of pathology in
chronically infected mice (29–31). In contrast, infectious virus
demonstrated by plaque assays starts to decline after 2 weeks
of infection and is present only at very low levels in chronically
infected mice, despite an abundance of viral antigen and RNA
(29, 32). Mice were treated with antiserum on 12 and 18 d.p.i.
and analyzed at 45 d.p.i. (27 days post-treatment interval). All
mice had spinal cord pathology, despite some mice having
very few infected cells in the sections that we sampled. Virus-
infected cells were found exclusively in the white matter tracts
of the spinal cord rather than the gray matter where neuronal
cell bodies are located. Virus expression was measured first
by counting the number of spinal cord quadrants with virus
antigen-positive cells. This revealed that mice treated with
MIG antiserum had a higher percentage of spinal cord quad-
rants with infected cells than mice treated with non-immune
Fig. 1. Chemokine antisera inhibit lymphocyte migration in vitro. The ability of anti-MIG and anti-RANTES antisera to block cell migration was
determined by utilizing a transwell chemotaxis assay. (A) Migration of CXCR3+ 300-19 in response to recombinant mouse MIG was reduced by
~75% upon pre-incubation with anti-MIG antiserum at varying concentrations. (B) Activated splenocytes taken from mice immunized with MHV
express the RANTES receptors CCR1 and CCR5 (55, 56). Migration of activated splenocytes in response to recombinant mouse RANTES was
reduced to background levels following pre-incubation with varying concentrations of anti-RANTES antisera. Data are representative of two
separate experiments.
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serum (P = 0.048; Fig. 4A). We also analyzed viral antigen by
counting the total number of infected cells as a function of
spinal cord area and found that RANTES antiserum-treated
mice had more infected cells relative to the area sampled,
compared with control mice (P = 0.048; Fig. 4B). Thus, anti-
MIG treatment resulted in a more widespread infection in the
spinal cord white matter, whereas anti-RANTES treatment
produced a higher overall level of virus expression. These
findings indicate that both chemokines participate in the
immune control of virus expression.
CD4 and CD8 expression patterns are unaltered by early
chemokine neutralization
CD4 and CD8 T cells are important in the control against
Theiler’s virus, and the Th1 subset of CD4 cells are the primary
responders to RANTES and MIG (33–35). We examined the
effects of chemokine neutralization on T cell infiltration by CD4
and CD8 immunostaining in spinal cord cross-sections. Mice
were treated with antisera at Days 12 and 18 post-infection,
a time at which lymphocyte infiltration is already present, then
examined at 27 days post-treatment. Tcells of both types were
Fig. 2. Viral and cytokine gene expression following chemokine neutralization. Chemokine antisera were administered to mice once or twice
between 10–17 d.p.i. RNA from spinal cords plus brain stems was isolated at 36 or 39 days following the end of treatment and analyzed by real-
time RT–PCR. Data from two experiments are combined. GAPDH levels were used to validate equivalent RNA input (A). VP2 viral capsid (B) and IL-
2 (C) were unchanged by the antisera treatments. IL-10 showed a statistically significant increase with anti-RANTES treatment (D). IL-2 and IL-10
levels were inversely related (E), and the IL-2/IL-10 ratio decreased in response to anti-RANTES (F).
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present in all mice examined but neither their abundance nor
the patterns of infiltration was obviously affected by MIG or
RANTES antisera (Fig. 5). Lymphocytes infiltrated spinal cords
extensively in all experimental groups and co-localized with
virus-infected cells. CD4 lymphocytes were located in the
perivasculature and the white matter parenchyma, whereas
CD8 lymphocytes were found primarily in the white matter
parenchyma. Due to the extent of infiltration, an accurate,
quantitative analysis of infiltration could not be performed.
However, from a qualitative perspective we conclude that
neutralization of MIG or RANTES did not have a significant or
sustained effect on infiltration of inflammatory cells by 1-month
post-treatment.
Chemokine neutralization increases spinal cord pathology
Our primary objective was to determine whether chemokine
neutralization altered spinal cord pathology. Two similar experi-
ments were conducted, and the data were combined. In the
first experiment mice were treated at 12 d.p.i. and examined at
45 d.p.i. (27 days post-treatment interval). In the second
experiment mice were treated at 12 and 18 d.p.i. and examined
at 48 d.p.i. (36 days post-treatment interval). A systematic
analysis of spinal cord cross-sections revealed differences in
the amount and severity of pathology related to chemokine
neutralization. In all experimental groups pathology was
confined to the white matter and was characterized by varying
degrees of lymphocyte and macrophage infiltration and myelin/
axon destruction. Measurement of the percentage of spinal
cord quadrants with lesions showed an increase in lesion
frequency in mice treated with MIG antiserum (34% of quad-
rants) as compared with the non-immune serum group (20% of
Fig. 3. IL-2 and IL-10 RNA levels correlate with virus expression. Data
from Fig. 2 were examined for correlations with VP2. IL-2 and IL-10
varied across only a 3-fold range (0.5 log units), whereas VP2 varied
across a 100-fold range (2 log units). IL-2 and the IL-2/IL-10 ratio
declined (A, C), and IL-10 increased (B) in proportion to increasing
VP2 levels.
Fig. 4. Chemokine neutralization increases viral antigen expression in
the spinal cord white matter. Mice were treated with the indicated
serum at 12 and 18 d.p.i., and spinal cord cross-sections were
immunostained for Theiler’s virus at 30 days following the end of
treatment. (A) MIG antiserum increased the number of spinal cord
quadrants showing pathology, compared with control mice. (B)
RANTES antiserum increased the total number of infected cells
relative to the area sampled compared with control mice.
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quadrants; P = 0.02; Fig. 6A). Moreover, the percentage of
spinal cord quadrants with inflammatory lesions was directly
proportional to the percentage of quadrants with viral antigen,
demonstrating the important relationship between spinal cord
white matter pathology and viral antigen load (Fig. 6B).
We assessed spinal cord pathology further by grading the
severity of each lesion on a 4-point scale using coded sections.
As shown in Fig. 7, the lowest grade of pathology (Grade 1)
consisted of mild lymphocyte infiltration without damage to the
normal tissue architecture. Grade 2 pathology was character-
ized by mild lymphocyte plus macrophage infiltration and
a small degree of demyelination. Grade 3 pathology was
characterized by moderate lymphocyte and macrophage
infiltration and significant demyelination. Grade 4 pathology
comprised extensive inflammation and severe tissue destruc-
tion. In mice given non-immune serum, the most common
lesions were Grade 1 and 2 (Fig. 7E). Grade 3 and 4 lesions
together represented only 13% of the total lesions in control
mice. In contrast, Grade 3 and 4 lesions together were three
times more common in mice given RANTES antiserum,
accounting for 35% of all lesions on average (P = 0.03 versus
control group Grade 3 + 4 lesions combined). Twenty-three
percent of lesions were Grade 3 or 4 after MIG neutralization,
although this level was not statistically different from control
mice. In conclusion, MIG neutralization resulted in an increase
in the number of lesioned spinal cord quadrants, in similarity to
the more widespread infection in these mice (previous
section), whereas RANTES neutralization increased the overall
severity of lesions, which correlated with a higher overall level
of expression of virus antigen.
Fig. 5. Infiltration of CD4 and CD8 lymphocytes is normal in mice at 4 weeks following anti-chemokine treatment. Longitudinal spinal cord sections
were immunostained for CD4 and CD8 at 27 days following the end of antiserum treatment. Large numbers of CD4 and CD8 lymphocytes were
found in the white matter with similar distributions in mice treated with non-immune, anti-RANTES or anti-MIG serum.
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Discussion
In the present report we demonstrate that RANTES and MIG
regulate virus expression and spinal cord white matter
pathology in the Theiler’s virus-induced disease. Lymphocyte
and macrophage infiltration into the CNS is vital for the
control of TMEV but it also secondarily causes demyelination
and axon destruction. The most logical hypothesis related to
chemokine neutralization is that reducing immune cell in-
filtration would elicit a rise in virus but a decline in immuno-
pathology. Looking at a time point when the consequences of
antiserum treatment could be significantly manifested, we
indeed found that RANTES neutralization and to a lesser extent
MIG neutralization elevated virus expression but unexpectedly
also caused more inflammation and demyelination in the spinal
cord. These data suggest that immune activity in SJL mice
attempts to restrict virus spread while limiting damage to
normal tissues and that RANTES and MIG participate in the
balancing of both these responses.
Many chemokines are produced during infection with the
Daniel’s strain of Theiler’s virus (4, 6, 11). Expression starts
within days of inoculation and lasts for several months in SJL
and other susceptible strains of mice. One of the most abun-
dantly produced chemokines, RANTES, is chemotactic for T
cells and monocytes/macrophages, whereas MIG regulates
migration of T cells but not monocytes (36). A comparison of
Theiler’s infection in a variety of mouse strains revealed that
virus persistence is one of the major determinants of chemokine
expression (11). Virus expression is also the major determin-
ant of CNS pathology. The present study showed that virus
antigen expression correlated with the extent of spinal cord
demyelination, which supports similar findings at later stages
of disease (29–31).
Considering these central roles for virus in inducing chemo-
kine expression and pathology, we hypothesize that the
principal effect of anti-RANTES and anti-MIG was to reduce
infiltration of antiviral lymphocytes and/or monocytes and that
pathology increased by 1-month post-treatment as a response
to higher virus expression at the protein level. Activated CD4
cells with a Th1 phenotype are the preferential targets of
RANTES and MIG (33, 37, 38) and are also known to be
important for virus control. Thus, a decline in antiviral activity is
expected from anti-RANTES and anti-MIG treatments. Also in
support of our hypothesis, virus titers and CNS pathology
increase following antibody-mediated depletion or genetic
knockout of CD4 lymphocytes (11, 23). Anti-chemokine treat-
ments had subtler effects than total CD4 depletion, likely
because a variety of chemokines contribute to infiltration of
lymphocytes or macrophages during infection.
Virus titers increased at the level of virus antigen but not viral
RNA. Trottier et al. (35) similarly found discordance between
viral RNA, which remains high and relatively constant through-
out the life of SJL mice, and infectious virus, which starts to
decline as early as 3 weeks post-infection (32). Thus, viral RNA
levels appear to be less responsive than virus antigen or
infectious virus (plaques) to immunomodulation. An important
question still to be resolved in the Theiler’s field is the
mechanism by which virus determines the extent of CNS
pathology. One hypothesis is that TMEV causes direct cytolysis
of CNS cells. The DA strain of Theiler’s virus persists in
oligodendrocytes, astrocytes and microglia/macrophages, but
direct cytolysis of these cells appears to be limited (39, 40). In
immunostained spinal cord sections we found only occasional,
highly distended, infected cells. In addition, immunocompro-
mised RAG/ mice infected with Theiler’s virus do not show
significant demyelination prior to death at 3 weeks post-
infection, even when virus is injected directly into the spinal
cord, implying a limited degree of cytolysis (M.R. unpublished
observations).
The more likely explanation is that the extent of virus
expression determines the strength of the immune reaction,
which in turn elicits secondary injury to myelin and other CNS
cells. One of the best examples of this mechanism involves the
adoptive transfer of immunocompetent splenocytes into
infected, immunodeficient SCID mice (41). Increasing the
number of transferred splenocytes is able to prevent TMEV-
induced mortality but also increases immunopathology.
Whereas transfer of very high numbers of splenocytes can
clear virus in SCID mice, SJL mice typically are unable to clear
Theiler’s virus. Lymphocytes reactive to the major Theiler’s
virus epitopes are rare in SJL and other susceptible mouse
Fig. 6. Chemokine neutralization increases spinal cord white matter
pathology. Infected mice were treated once or twice with the indicated
serum between 12–18 d.p.i., and spinal cord cross-sections were
examined at 27 or 36 days following the end of treatment. Data from
both experiments were combined. (A) The percentage of spinal cord
quadrants showing white matter pathology (4 quadrants per section
and 10 sections per cord were examined) was higher following anti-
MIG treatment as compared with control serum treatment. (B) The
percentage of cord quadrants with white matte pathology correlated
with the percentage of quadrants with infected cells.
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strains, in contrast to resistant strains such as C57BL/10 mice
(15). The virus-specific response of only a minority of
lymphocytes might partially explain why we did not observe
obvious alterations in CD4 or CD8 lymphocyte infiltration by
immunostaining. Another possible explanation is that a signifi-
cant number of infiltrating lymphocytes or monocytes/macro-
phages might have been responding secondarily to tissue
damage or might have had affinities for other chemokines. We
also recognize that chemokine-neutralizing activity might have
subsided over time and that specific lymphocyte infiltration
might have rebounded by 1-month post-treatment.
The inverse relationships between IL-2 and IL-10 RNA levels
and the correlations of both cytokines with viral RNA were
intriguing, especially since IL-2 and IL-10 RNA varied only
across a 3-fold range whereas virus varied across a 100-fold
range. Finding strong correlations within this context suggests
that the changes in IL-2 and IL-10 were biologically relevant. A
narrow window of regulation might explain why it has been
difficult to associate the various aspects of Theiler’s disease
(e.g. susceptibility versus resistance) or multiple sclerosis (e.g.
inactive versus active) with particular cytokine profiles (42–50).
It is tempting to speculate that these changes were indicative of
Fig. 7. Spinal cord pathology in infected mice. (A–D) Plastic-embedded, spinal cord sections were histologically stained to show lymphocyte and
macrophage infiltration, demyelination and damage to the CNS. Sections were coded to blind the observer to treatment group and scored, based
on the following scheme: Grade 1 ¼ mild inflammation; Grade 2 ¼ moderate inflammation; Grade 3 ¼ mild–severe inflammation with moderate
demyelination; Grade 4 ¼ severe inflammation, demyelination and tissue damage. (E) Quantitative data shows that moderate to severe lesions
(Grade 3 and 4 combined) were more abundant following anti-RANTES treatment as compared with control serum treatment (P ¼ 0.03) but not
following anti-MIG treatment (P ¼ 0.14 versus control group Grade 3 + 4).
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the proportions of Th1 and Th2 lymphocytes. For example, an
increase in virus concurrent with a decrease in IL-2 is
consistent with the hypothesis that IL-2-expressing Th1
lymphocytes are important for virus control. However, a suitable
explanation probably is more complicated because two other
cytokines representative of Th1 and Th2 lymphocytes, IFN-c
and IL-4, did not show correlations with viral RNA. Glial cells
also express many of these cytokines as well as the chemokine
receptor, CXCR3, which confounds conclusions about the
specific responses of infiltrating cells (51–54).
The major implication from our study is that even short-term
modulation of the immune response can significantly influence
spinal cord pathology in the long term. A question for future
studies is whether the increases in virus expression and
pathology are sustained, or whether antiviral mechanisms are
able to reduce these parameters back to a level characteristic
of untreated mice. Another question is whether more neuro-
logical dysfunction eventually develops in mice in which
chemokines are neutralized. Chemokine neutralization, al-
though not immediately impacting function, may accelerate the
onset and eventual severity of deficits. From the standpoint of
human disease, chemokine neutralization represents a pro-
mising therapy for autoimmune diseases where lymphocyte
dysregulation and autoreactivity are the primary etiologies. In
contrast, our findings caution against the use of chemokine
neutralization where viral etiologies are suspected. Even mild
and apparently benign treatments may have adverse effects
later in disease.
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Abbreviations
CNS central nervous system
d.p.i. days post-infection
DA Daniel’s strain of Thelier’s virus
IP-10 interferon-c inducible protein-10
MHV mouse hepatitis virus
MIG monokine induced by IFN-c
p.f.u. plaque-forming unit
RANTES regulated on activation, normal T cell expressed and
secreted
RT reverse transcriptase
TMEV Theiler’s murine encephalomyelitis virus
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